

Emyria receives \$1,162,134 R&D tax incentive refund

Highlights:

- Emyria has received a R&D Tax incentive refund of \$1,161,134
- Funds are in addition to the \$5m, now received, from Tattarang's strategic investment announced on Monday, November 22nd, 2021
- Emyria is in a strong cash position to accelerate the development of its cannabinoid, MDMA-assisted therapy and MDMA-analogue programs

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company, is pleased to announce that it has received a Research and Development (R&D) Tax Incentive refund of \$1,162,134 for the financial year 2020/2021.

Emyria Managing Director Dr Michael Winlo said: "Combined with the recent strategic investment from Tattarang, this R&D tax incentive refund strengthens Emyria's capital position and enables us to accelerate our drug registration programs. We look forward to providing further updates to the market in due course"

The R&D Tax Incentive is an Australian Government program to support Australian companies to undertake R&D activities in Australia, under which eligible companies can receive cash rebates of up to 43.5% of eligible expenditure on R&D activities.

The Company also wishes to advise that the strategic Placement with Tattarang has now settled and the Shares will be issued today in accordance with the agreement.

This announcement has been approved and authorised for release by the Board of Emyria Limited.

For further information on **Emyria**, please contact:

Dr. Michael Winlo
Managing Director
1300 436 363

mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076

lexi@janemorganmanagement.com.au

Andrew Williams
Media Relations
+61 (0) 412 614 125

andreww@profilemedia.com.au

emyria

About Emyria (www.emyria.com)

Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.

Emyria's Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.